Table 4.
Drug prices of individual ICIs over time, 2011–21 (reimbursement in dollar amounts per prescription acts as a proxy for average drug price)
| Year | Average drug price ($) | |||||
|---|---|---|---|---|---|---|
| Ipilimumab | Pembrolizumab | Nivolumab | Atezolizumab | Avelumab | Cemiplimab | |
| 2011 | 29,795.88 | – | – | – | – | – |
| 2012 | 28,599.46 | – | – | – | – | – |
| 2013 | 31,865.46 | – | – | – | – | – |
| 2014 | 32,281.06 | 10,233.99 | – | – | – | – |
| 2015 | 32,176.75 | 9604.97 | 7801.43 | – | – | – |
| 2016 | 35,298.09 | 7883.59 | 5218.57 | 7801.43 | – | – |
| 2017 | 46,553.38 | 9204.39 | 5530.45 | 8570.31 | – | – |
| 2018 | 24,800.78 | 9590.90 | 5859.00 | 9264.70 | 3853.33 | – |
| 2019 | 17,737.11 | 8817.00 | 6881.18 | 8777.38 | 4008.53 | 6439.80 |
| 2020 | 15,971.62 | 8973.20 | 7336.69 | 7870.08 | 4637.22 | 7046.47 |
| 2021 | 14,368.96 | 9384.30 | 7176.41 | 8716.94 | 5977.11 | 7233.04 |
| Average | 18,799.66 | 9272.23 | 6365.98 | 8677.51 | 5732.67 | 7184.48 |
ICI immune checkpoint inhibitors